enter here
A Study of Psilocybin for Major Depressive Disorder (MDD)
About the study
NCT Trial Number
NCT03866174
The drug being studied
Psilocybin
Sponsored by
Usona Institute
Signant Health
The Emmes Company, LLC
Trial Start Date
Oct-19
About the participants
Age seeking
21 Years to 65 Years
gender
All
Primary condition of volunteers accepted
Depression
Accepts healthy volunteers?
Yes
The purpose of this study is to evaluate the potential efficacy of a single oral dose of psilocybin for depression.
Locations
United States, California
University of California, San Francisco
San Francisco, California, United States, 94121
Contact: Catriona S Miller, BA
510-985-3522
psil_201@ucsf.edu
Contact: Jennifer M Mitchell, PhD
510-985-3921
psil_201@ucsf.edu
United States, Connecticut
Yale University
New Haven, Connecticut, United States, 06520
Contact: Jane Wanyiri, RN
203-764-9131
jane.wanyiri@yale.edu
Contact: Elizabeth Cooper, BS
203-764-9182
elizabeth.cooper@yale.edu
United States, Florida
Segal Trials
Lauderhill, Florida, United States, 33319
Contact: Orbrena Wellons, MA
954-990-6326
owellons@segaltrials.com
Contact: Courtney Talbert, MS
954-990-6326
ctalbert@segaltrials.com
United States, Illinois
Great Lakes Clinical Trials
Chicago, Illinois, United States, 60640
Contact: Amber Holst
872-529-8805
aholst@greatlakesclinicaltrials.com
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21229
Contact: Nathan Sepeda, BS
410-550-2253 nsepeda1@jhmi.edu
Contact: Jessica Lombardi, BS
410-550-5243
jlomba15@jhmi.edu